In relation to disease management, specifically regarding medications, the American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [22] recommend the use of ACE inhibitors or angiotensin receptor blockers for patients with DM who also have comorbid hypertension and microalbuminuria. This evidence concerns the gene ACE and kidney disorder.